Cooper Companies (NASDAQ:COO) Cut to Market Perform at William Blair

William Blair cut shares of Cooper Companies (NASDAQ:COO) from an outperform rating to a market perform rating in a research report report published on Thursday morning, Marketbeat.com reports.

A number of other equities research analysts have also issued reports on the company. Bank of America reiterated a “neutral” rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday. Mizuho set a $85.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, June 4th. UBS Group decreased their price target on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday. Robert W. Baird set a $61.00 price objective on shares of Cooper Companies and gave the company a “neutral” rating in a research report on Thursday. Finally, BNP Paribas Exane dropped their price objective on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday, June 8th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $71.47.

Cooper Companies Stock Down 0.5%

Shares of Cooper Companies stock opened at $53.91 on Thursday. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The stock has a market cap of $10.25 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a current ratio of 1.22, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The company has a fifty day moving average price of $71.62 and a 200 day moving average price of $69.70.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm’s revenue was up .5% compared to the same quarter last year. During the same period last year, the company posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts forecast that Cooper Companies will post 4.53 earnings per share for the current fiscal year.

Cooper Companies announced that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Root Financial Partners LLC grew its position in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares in the last quarter. Avalon Trust Co acquired a new stake in shares of Cooper Companies during the 2nd quarter valued at approximately $25,000. SJS Investment Consulting Inc. raised its position in shares of Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 187 shares in the last quarter. Elevation Wealth Partners LLC lifted its stake in Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC bought a new position in Cooper Companies during the second quarter worth $30,000. Institutional investors own 24.39% of the company’s stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.